Literature DB >> 22313961

HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy.

Anna C Hearps1, Anna Maisa, Wan-Jung Cheng, Thomas A Angelovich, Gregor F Lichtfuss, Clovis S Palmer, Alan L Landay, Anthony Jaworowski, Suzanne M Crowe.   

Abstract

OBJECTIVES: To compare the impact of HIV infection and healthy ageing on monocyte phenotype and function and determine whether age-related changes induced by HIV are reversed in antiretroviral treated individuals.
DESIGN: A cross sectional study of monocyte ageing markers in viremic and virologically suppressed HIV-positive males aged 45 years or less and age-matched and elderly (≥65 years) HIV-uninfected individuals.
METHODS: Age-related changes to monocyte phenotype and function were measured in whole blood assays ex vivo on both CD14(++)CD16(-) (CD14(+)) and CD14(variable)CD16(+) (CD16(+)) subsets. Plasma markers relevant to innate immune activation were measured by ELISA.
RESULTS: Monocytes from young viremic HIV-positive males resemble those from elderly controls, and show increased expression of CD11b (P < 0.0001 on CD14(+) and CD16(+)subsets) and decreased expression of CD62L and CD115 (P = 0.04 and 0.001, respectively, on CD14(+) monocytes) when compared with young uninfected controls. These changes were also present in young virologically suppressed HIV-positive males. Innate immune activation markers neopterin, soluble CD163 and CXCL10 were elevated in both young viremic (P < 0.0001 for all) and virologically suppressed (P = 0.0005, 0.003 and 0.002, respectively) HIV-positive males with levels in suppressed individuals resembling those observed in elderly controls. Like the elderly, CD14(+) monocytes from young HIV-positive males exhibited impaired phagocytic function (P = 0.007) and telomere-shortening (P = 0.03) as compared with young uninfected controls.
CONCLUSION: HIV infection induces changes to monocyte phenotype and function in young HIV-positive males that mimic those observed in elderly uninfected individuals, suggesting HIV may accelerate age-related changes to monocytes. Importantly, these defects persist in virologically suppressed HIV-positive individuals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22313961     DOI: 10.1097/QAD.0b013e328351f756

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  83 in total

1.  Reduced CD14 expression on classical monocytes and vascular endothelial adhesion markers independently associate with carotid artery intima media thickness in chronically HIV-1 infected adults on virologically suppressive anti-retroviral therapy.

Authors:  Jason D Barbour; Emilie C Jalbert; Dominic C Chow; Louie Mar A Gangcuangco; Philip J Norris; Sheila M Keating; John Heitman; Lorna Nagamine; Todd Seto; Lishomwa C Ndhlovu; Beau K Nakamoto; Howard N Hodis; Nisha I Parikh; Cecilia M Shikuma
Journal:  Atherosclerosis       Date:  2013-10-31       Impact factor: 5.162

Review 2.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

3.  Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir.

Authors:  Marcin Moniuszko; Namal P M Liyanage; Melvin N Doster; Robyn Washington Parks; Kamil Grubczak; Danuta Lipinska; Katherine McKinnon; Charles Brown; Vanessa Hirsch; Monica Vaccari; Shari Gordon; Poonam Pegu; Claudio Fenizia; Robert Flisiak; Anna Grzeszczuk; Milena Dabrowska; Marjorie Robert-Guroff; Guido Silvestri; Mario Stevenson; Joseph McCune; Genoveffa Franchini
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

4.  Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women.

Authors:  Kathleen V Fitch; Suman Srinivasa; Suhny Abbara; Tricia H Burdo; Kenneth C Williams; Peace Eneh; Janet Lo; Steven K Grinspoon
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

5.  Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction.

Authors:  Robert C Kalayjian; John Spritzler; Roy M Matining; Susan A Fiscus; Barry H Gross; Isaac R Francis; Richard B Pollard; Michael M Lederman; Alan Landay
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

6.  Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Res Hum Retroviruses       Date:  2018-11-27       Impact factor: 2.205

7.  Effects of Well-Controlled HIV Infection on Complement Activation and Function.

Authors:  Alexandria E-B Rossheim; Tina D Cunningham; Pamela S Hair; Tushar Shah; Kenji M Cunnion; Stephanie B Troy
Journal:  J Acquir Immune Defic Syndr       Date:  2016-09-01       Impact factor: 3.731

8.  High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women.

Authors:  Emmanouil Papasavvas; Lea F Surrey; Deborah K Glencross; Livio Azzoni; Jocelin Joseph; Tanvier Omar; Michael D Feldman; Anna-Lise Williamson; Maureen Siminya; Avril Swarts; Xiangfan Yin; Qin Liu; Cynthia Firnhaber; Luis J Montaner
Journal:  Oncoimmunology       Date:  2016-01-19       Impact factor: 8.110

9.  HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance P.

Authors:  Florin Tuluc; John Meshki; Sergei Spitsin; Steven D Douglas
Journal:  J Leukoc Biol       Date:  2014-02-27       Impact factor: 4.962

Review 10.  Aging of the human innate immune system in HIV infection.

Authors:  Heidi J Zapata; Albert C Shaw
Journal:  Curr Opin Immunol       Date:  2014-07-02       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.